TARGET PharmaSolutions, Inc., a company focused on real-world evidence, has announced a strategic partnership with Bristol Myers Squibb (BMS) for its TARGET-IBD study which includes a biorepository which its stakeholders can access for translational studies of viral resistance, genomics and biomarkers to further their research of inflammatory bowel disease.
TARGET PharmaSolutions, founded in 2015, headquartered in Chapel Hill, North Carolina, USA, is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting.
BMS, a pharmaceutical company with a range of biologic products, formed from the merger of Bristol Myers and Squibb in 1989. Bristol Myers was founded in 1887 and Squibb in 1858. BMS is headquartered New York City, USA, with a market capitalization of USD 87 billion as of December 9, 2018.
TARGET-IBD is a longitudinal observational study that evaluates patients with Inflammatory Bowel Disease, including adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate Colitis. TARGET-IBD has enrolled over 1,850 patients to date at 30 investigative sites. TARGET-IBD is led by an academic steering committee co-chaired by Bruce Sands, MD (Mount Sinai), David Rubin, MD (University of Chicago), and Millie Long, MD (University of North Carolina).
The TARGET-IBD study design is disease focused, not treatment-specific, allowing for continuous acquisition of natural history and outcomes data, including patient reported outcomes (PROs), as new treatments continue to enter the market and clinical programs evolve.
“TARGET-IBD continues to collect valuable real-world data which enhances our understanding of the natural history of inflammatory bowel disease and the impact of different treatment paradigms on patient populations over time. The outcomes from real-world evidence can help doctors as they work to provide treatments to individual patients in real-life settings. This is particularly important given the ongoing innovation in the treatment of inflammatory bowel disease.” – Dr. Millie Long, University of North Carolina
“TARGET-IBD continues to make tremendous progress by enrolling a diverse patient cohort – including adult and pediatric patients –from a network of academic and community sites. The meticulously detailed real-world data it is collecting from these patients, such as severity of disease, is valuable for TARGET-IBD industry partners like BMS as they work to develop treatments to enhance patient outcomes. Our partnership demonstrates a shared vision of advancing IBD research and builds on our current partnership with Bristol-Myers Squibb for TARGET-NASH and TARGET-HCC.” – Meg Powell, Pharm.D., CEO of TARGET PharmaSolutions